FLUTICASONE PROPIONATE

Drug Teva Pharmaceuticals USA, Inc.
Total Payments
$3.8M
Transactions
716
Doctors
2
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2017 $3.8M 716 2

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $3.8M 716 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
FSS-AS-30003 Teva Pharmaceuticals USA, Inc. $3.6M 2
FSS-PK-10007 Teva Pharmaceuticals USA, Inc. $226,357 0
FPS-AS-202 Teva Pharmaceuticals USA, Inc. $1,890 0

Top Doctors Receiving Payments for FLUTICASONE PROPIONATE

Doctor Specialty Location Total Records
Unknown — Killeen, TX $3.8M 708
, MD Pediatric Pulmonology Oklahoma City, OK $12,628 7
, M.D Pulmonary Disease Canton, OH $4,500 1

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $3.8M
  • Total Doctors 2
  • Transactions 716

About FLUTICASONE PROPIONATE

FLUTICASONE PROPIONATE is a drug associated with $3.8M in payments to 2 healthcare providers, recorded across 716 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..

Payment data is available from 2017 to 2017. In 2017, $3.8M was paid across 716 transactions to 2 doctors.

The most common payment nature for FLUTICASONE PROPIONATE is "Unspecified" ($3.8M, 100.0% of total).

FLUTICASONE PROPIONATE is associated with 3 research studies, including "FSS-AS-30003" ($3.6M).